Cardiolipin, the Mitochondrial Signature Lipid: Implication in Cancer

Seyedeh Tayebeh Ahmadpour (1) , Karine Mahéo (1) , Stéphane Servais (1) , Lucie Brisson (1) , Jean-François Dumas (1)

1 N2Cox - Niche, Nutrition, Cancer et métabolisme oxydatif

Cardiolipins (CLs) are specific phospholipids of the mitochondria composing about 20% of the inner mitochondria membrane (IMM) phospholipid mass. Dysregulation of CL metabolism has been observed in several types of cancer. In most cases, the evidence for a role for CL in cancer is merely correlative, suggestive, ambiguous, and cancer-type dependent. In addition, CLs could play a pivotal role in several mitochondrial functions/parameters such as bioenergetics, dynamics, mitophagy, and apoptosis, which are involved in key steps of cancer aggressiveness (i.e., migration/invasion and resistance to treatment). Therefore, this review focuses on studies suggesting that changes in CL content and/or composition, as well as CL metabolism enzyme levels, may be linked with the progression and the aggressiveness of some types of cancer. Finally, we also introduce the main mitochondrial function in which CL could play a pivotal role with a special focus on its implication in cancer development and therapy.

Mots clés: cardiolipin; cancer; mitochondria

Domaines: Cancer; Biologie cellulaire

Seyedeh Tayebeh Ahmadpour, Karine Mahéo, Stéphane Servais, Lucie Brisson, Jean-François Dumas. Cardiolipin, the Mitochondrial Signature Lipid: Implication in Cancer. International Journal of Molecular Sciences, 2020, 21 (21), pp.8031. ⟨10.3390/ijms21218031⟩. ⟨hal-03335862⟩